A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

July 7, 2026 updated by: Novo Nordisk A/S

A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Withdrawn

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Bulgaria
      • Burgas, Bulgaria, 8000
        • IPSMC - Dr. Nikolay Kostadinov EOOD
      • Dobrich, Bulgaria, 9300
        • Medical Center Viva Feniks OOD
      • Kyustendil, Bulgaria, 2500
        • IPSOMC Dr. Miglena Rizova Ltd.
      • Plovdiv, Bulgaria, 4006
        • DCC Iztok EOOD
      • Plovdiv, Bulgaria, 4002
        • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Endocrinology
      • Plovdiv, Bulgaria, 4004
        • MHAT Sveta Karidad EAD
      • Plovdiv, Bulgaria, 4002
        • UMHAT Pulmed OOD - Plovdiv, Department of Endocrinology
      • Razgrad, Bulgaria, 7200
        • Medical Centre Razgrad OOD
      • Sofia, Bulgaria, 1233
        • DCC VII - Sofia EOOD, Endocrinology
      • Sofia, Bulgaria, 1618
        • Diagnostic-Consultative Anti-Aging and Rejuvenation Center Hill Clinic EAD
      • Varna, Bulgaria, 9020
        • AIPSMC Dr. Artin Magardichyan EOOD
      • Varna, Bulgaria, 9000
        • Medical Center Medical Plus EOOD
      • Varna, Bulgaria, 9009
        • DCC Mladost - M Varna OOD
  • Denmark
      • Gandrup, Denmark, 9362
        • Sanos Clinic - Gandrup
      • Viborg, Denmark, 8800
        • Regionshospitalet Viborg - Karkirurgisk Afsnit
    • Region Syddanmark
      • Vejle, Region Syddanmark, Denmark, 7100
        • Sanos Clinic - Vejle
  • Greece
      • Athens, Greece, 11525
        • 251 Air Force General Hospital - Department of Endocrinology & Diabetes
      • Athens, Greece, 11527
        • General Hospital Of Athens G Gennimatas - Department of Endocrinology
      • Athens, Greece, 11527
        • Laiko General Hospital Of Athens - A' Propaedeutic Clinic of Internal Medicine-Diabetes Centre
      • Marousi, Greece, 15125
        • Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit
      • Palaió Fáliro, Greece, 17562
        • Athens Medical Center S.A. (Iatriko P. Falirou) - Diabetes and Clinical Research Center
      • Thessaloniki, Greece, 546 35
        • General Hospital Of Thessaloniki G Gennimatas - Internal Medicine Clinic
      • Thessaloniki, Greece, 57001
        • Thermi Clinic S.A. - Diabetes and Internal Medicine Department
  • Hungary
      • Budapest, Hungary, 1089
        • ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.
    • Bekes County
      • Orosháza, Bekes County, Hungary, 5900
        • Arina Trial Research Kft.
    • Csongrád-Csanád
      • Szeged, Csongrád-Csanád, Hungary, 6725
        • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Hungary, 4032
        • Debreceni Egyetem
      • Debrecen, Hajdú-Bihar, Hungary, 4025
        • Belinus Bt.
    • Szabolcs-Szatmar Varmegye
      • Nyíregyháza, Szabolcs-Szatmar Varmegye, Hungary, 4405
        • Borbánya Praxis E.Ü. Kft.
  • Malaysia
      • Kuala Kedah, Malaysia, 05460
        • Klinik Kesihatan Kuala Kedah
      • Malacca, Malaysia, 75400
        • Hospital Melaka
      • Sabak Bernam, Malaysia, 88300
        • Hospital Queen Elizabeth II
    • Kelantan
      • Kota Bharu, Kelantan, Malaysia, 15586
        • Hospital Raja Perempuan Zainab II
    • Kuala Lumpur
      • Cheras, Kuala Lumpur, Malaysia, 56000
        • Hospital Canselor Tuanku Muhriz UKM
      • Lembah Pantai, Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
    • Perak
      • Seri Manjung, Perak, Malaysia, 32040
        • Hospital Seri Manjung
    • Pulau Pinang
      • George Town, Pulau Pinang, Malaysia, 10990
        • Hospital Pulau Pinang
    • Sarawak
      • Miri, Sarawak, Malaysia, 98000
        • Hospital Miri
    • Selangor
      • Rawang, Selangor, Malaysia, 48050
        • Klinik Kesihatan Kuang
      • Sungai Buloh, Selangor, Malaysia, 47000
        • University Technology MARA (UiTM) - Sg Buloh
  • Poland
      • Bialystok, Poland, 15-281
        • Gabinet Leczenia Otylosci i Chorob Dietozaleznych
      • Bydgoszcz, Poland, 85-231
        • Centrum Medyczne Kermed Renata Bijata-Bronisz I Ewa Kowalinska Sp. j.
      • Bytom, Poland, 41-902
        • Niepubliczny Zakład Opieki Zdrowotnej BIF-MED S.C. Arkadiusz Wawiernia, Mariola Roykiewicz, Rafał Roykiewicz
      • Gdansk, Poland, 80-382
        • Synexus Polska Sp. z o.o. Oddzial w Gdansku
      • Gdansk, Poland, 80-298
        • NZOZ Mediart Centrum Zdrowia Matarnia
      • Mysłowice, Poland, 41-400
        • ID Clinic Arkadiusz Pisula
      • Warsaw, Poland, 02-672
        • Synexus Polska Sp. z o.o. Oddzial w Warszawie
      • Warsaw, Poland, 00-710
        • Clinical Best Solutions Sp. z o.o., Sp. k
      • Włocławek, Poland, 87-800
        • Kardio Life - Tomasz Borkowski
      • Zamość, Poland, 22-400
        • Velocity Nova Sp. z o.o.
      • Żyrardów, Poland, 96-300
        • Prywatna Praktyka Lekarska Anna Chudoba
  • Portugal
      • Braga, Portugal, 4710-243
        • ULS De Braga, E.P.E. - Hospital de Braga_Centro Clínico Académico
      • Guimarães, Portugal, 4835-044
        • ULS Do Alto Ave, E.P.E - HSOG_Centro de Investigação Clínica
      • Leiria, Portugal, 2400-110
        • Hospital São Francisco, S.A_EECC
      • Lisbon, Portugal, 1250-189
        • APDP - Associação Protectora dos Diabéticos de Portugal
      • Montijo, Portugal, 2870-100
        • Affidea Montijo - UCardio
      • Ponte de Lima, Portugal, 4990-029
        • Cardiolima Centro Diagnostico Cardio-Pulmonar De Ponte De Lima Lda
  • Romania
      • Brasov, Romania, 500102
        • Thera Card S.R.L
      • Bucharest, Romania, 010073
        • Kilostop Junior SRL
      • Galati, Romania, 800291
        • SC Diamed Obesity SRL
      • Iași, Romania, 700620
        • Arcadia Policlinic SRL
      • Satu Mare, Romania, 440055
        • Spital Judetean De Urgenta Satu Mare
      • Sibiu, Romania, 550371
        • SC Gensan SRL, Policlinica ASTRA
      • Târgu Mureş, Romania, 540136
        • Spitalul Clinic Judetean de Urgenta Targu Mures
  • Slovakia
      • Martin, Slovakia, 036 01
        • MED-CENTRUM, s.r.o.
      • Nové Zámky, Slovakia, 940 01
        • KARDIOMED NZ, s.r.o.
      • Prešov, Slovakia, 080 01
        • SVAJDLEROVA, s.r.o.
      • Rimavská Sobota, Slovakia, 979 01
        • ENRIN, s.r.o.
      • Rožňava, Slovakia, 04801
        • DIAB s.r.o.
  • South Africa
    • Gauteng
      • Johannesburg, Gauteng, South Africa, 1818
        • Soweto Clinical Trial Centre
      • Johannesburg, Gauteng, South Africa, 2193
        • Ezintsha Research Centre
      • Midrand, Gauteng, South Africa, 1685
        • Dr A Jacovides and Partners Inc
    • KwaZulu-Natal
      • Durban, KwaZulu-Natal, South Africa, 4170
        • Dr T Padayachee
      • Durban, KwaZulu-Natal, South Africa, 4091
        • Dr Vawda's site
      • KwaDukuza, KwaZulu-Natal, South Africa, 4449
        • Clinical Research Institute of South Africa
    • Lenasia
      • Gauteng, Lenasia, South Africa, 1827
        • Dr Moosa's Rooms
  • Switzerland
      • Lucerne, Switzerland, 6004
        • Luzerner Kantonsspital
      • Olten, Switzerland, 4600
        • Kantonsspital Olten
      • Sankt Gallen, Switzerland, 9016
        • Stoffwechselzentrum St. Gallen
      • Zollikerberg, Switzerland, 8125
        • Diabetes Adipositas Zentrum Zürich
  • Taiwan
      • Chiayi City, Taiwan, 600
        • Ditmanson Medical Foundation Chia-Yi Christian Hospital
      • Taichung, Taiwan, 433
        • Kuang Tien General Hospital
      • Tainan, Taiwan, 710
        • Chi Mei Medical Center
      • Taipei, Taiwan, 116
        • Taipei Municipal Wan Fang Hospital_Division of Endocrinology & Metabolism
  • Thailand
      • Bangkok, Thailand, 10700
        • Siriraj Hospital
      • Bangkok, Thailand, 10400
        • Ramathibodi Hospital
      • Chiang Mai, Thailand, 50200
        • RIHES-CMU_Research Institute for Health Sciences
      • Chiang Mai, Thailand, 50200
        • Maharaj Nakorn Chiang Mai
      • Pathum Thani, Thailand, 12120
        • Thammasat Hospital_CRC
    • Changwat Songkhla
      • Hat Yai, Changwat Songkhla, Thailand, 90110
        • Hat Yai hospital
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35233
        • Uni of Alabama at Birmingham
      • Pelham, Alabama, United States, 35124
        • Cahaba Research
    • California
      • Hawthorne, California, United States, 90250
        • Advanced Investigative Medicine, Inc.
      • Santa Ana, California, United States, 92701
        • Southern Cal Clinical Research
      • Spring Valley, California, United States, 91978
        • Encompass Clinical Research_Spring Valley
    • Connecticut
      • Waterbury, Connecticut, United States, 06708
        • Chase Medical Research LLC
    • Florida
      • Hollywood, Florida, United States, 33024
        • NextPhase Research
      • Miami, Florida, United States, 33144
        • Oceane 7 Medical & Research Center, Inc.
      • Tampa, Florida, United States, 33613
        • ForCare Clinical Research
    • Georgia
      • Snellville, Georgia, United States, 30078
        • EBGS Clinical Research Center, LLC
      • Union City, Georgia, United States, 30291
        • Rophe Adult & Pediatric Medicine
    • Idaho
      • Idaho Falls, Idaho, United States, 83404
        • Rocky Mountain Diabetes and Osteoporosis Center
    • Illinois
      • Champaign, Illinois, United States, 61822
        • PGM Research of Christie Clinic
    • Michigan
      • Troy, Michigan, United States, 48098
        • Arcturus HC PLC Troy Med Res
    • Mississippi
      • Brookhaven, Mississippi, United States, 39601
        • Anointed Nephrology & HTN, LLC
    • Nevada
      • Las Vegas, Nevada, United States, 89148
        • Palm Research Center Inc.
      • Las Vegas, Nevada, United States, 89128
        • Palm Research Center Inc.
    • New York
      • New York, New York, United States, 10021
        • Weill Medical College of Cornell University
    • Oklahoma
      • Norman, Oklahoma, United States, 73069
        • Alliance for Multispecialty Research
    • South Carolina
      • Greer, South Carolina, United States, 29650
        • Tribe Clinical Research LLC
      • Little River, South Carolina, United States, 29566
        • Walker Family Care
    • Texas
      • Austin, Texas, United States, 78704
        • Elligo Clin Res Centre
      • Dallas, Texas, United States, 75390-9302
        • University of Texas Southwestern Medical Center
      • Harlingen, Texas, United States, 78550
        • Forefront Med Res Inst PLLC
    • Virginia
      • Newport News, Virginia, United States, 23606
        • TPMG Clinical Research
    • Washington
      • Olympia, Washington, United States, 98502
        • Capital Clin Res Ctr,LLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female (sex at birth)
  • Age 18 years or above at the time of signing the informing consent.
  • Body Mass Index (BMI) is greater than or equal to (>= ) 30.0 kilograms per square metre (kg/m^2) or BMI >= 27.0 kg/m^2 with the presence of at least one obesity-related complication including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Exclusion Criteria:

  • Glycosylated haemoglobin (HbA1c) >= 6.5 % (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes.
  • Previous exposure to CagriSema in a clinical study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: CagriSema B in device 2 + Placebo in device 1
Participants will receive CagriSema B in device 2 followed by placebo matched to CagriSema in device 1 subcutaneously once weekly in a dose escalation manner for 16 weeks until the target maintenance dose and further continue to receive the same dose for up to 44 weeks.
Drug: Cagrisema
Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.
Experimental: CagriSema in device 1 + Placebo in device 2
Participants will receive CagriSema in device 1 followed by placebo matched to CagriSema B in device 2 subcutaneously once weekly in a dose escalation manner for 16 weeks until the target maintenance dose and further continue to receive the same dose for up to 44 weeks.
Drug: Cagrisema
Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.
Placebo Comparator: Placebo in device 1 + Placebo in device 2
Participants will receive placebo matched to Cagrisema in device 1 followed by placebo matched to CagriSema B in device 2 subcutaneously once weekly for up to 44 weeks.
Drug: Placebo CagriSema
Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Relative change in body weight
Time Frame: From baseline (week 0) to end of treatment (week 44)
Measured in percentage (%).
From baseline (week 0) to end of treatment (week 44)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number of TEAEs (treatment emergent adverse events)
Time Frame: From baseline (week 0) to end of study (week 51)
Measured in count of events.
From baseline (week 0) to end of study (week 51)
Number of TESAEs (Treatment emergent serious adverse events)
Time Frame: From baseline (week 0) to end of study (week 51)
Measured in count of events.
From baseline (week 0) to end of study (week 51)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Novo Nordisk A/S

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Transparency dept. 2834, Novo Nordisk A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 22, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 29, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 17, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 21, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 21, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 9, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 7, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NN9838-8166
  • U1111-1317-0133 (Other Identifier: World Health Organization)
  • 2024-520448-41 (Other Identifier: European Medical Agency (EMA))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings